Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Up 11.6%
Xenon Pharmaceuticals Inc (NASDAQ:XENE) shares rose 11.6% on Wednesday . The company traded as high as $17.40 and last traded at $17.18, approximately 553,058 shares changed hands during trading. An increase of 70% from the average daily volume of 324,642 shares. The stock had previously closed at $15.40.
XENE has been the topic of a number of recent research reports. ValuEngine lowered shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, December 3rd. Zacks Investment Research upgraded shares of Xenon Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $16.00 price target on the stock in a research report on Saturday, January 11th. BidaskClub lowered shares of Xenon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 4th. Finally, William Blair began coverage on shares of Xenon Pharmaceuticals in a report on Wednesday, January 8th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Xenon Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $19.67.
The company has a current ratio of 8.25, a quick ratio of 8.25 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $437.45 million, a price-to-earnings ratio of -11.99 and a beta of 1.50. The firm’s fifty day simple moving average is $15.31 and its two-hundred day simple moving average is $11.25.
Xenon Pharmaceuticals Company Profile (NASDAQ:XENE)
Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.
Recommended Story: How Do You Make Money With Penny Stocks?
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.